Results 21 to 30 of about 1,649 (205)

Epidural Lornoxicam Administration-İnnocent

, 2006
Epidural Lornoxicam Administration ...
Erkin, Yüksel
core   +2 more sources

Design and Optimization of Lornoxicam Dispersible Tablets Using Quality by Design (QbD) Approach

Pharmaceuticals, 2022
The present study aims to design and optimize the lornoxicam dispersible tablet (LXDT) formulation using the Quality by design (QbD) approach. A randomized Box–Behnken experimental design was used to characterize the effect of the critical factors, such ...
Nawaf Almotairi, Gamal M. Mahrous, Saleh Al-suwayeh, Mohsin Kazi   +3 more
doaj   +1 more source

Comparison of tramadol and lornoxicam in intravenous regional anesthesia: a randomized controlled trial

Brazilian Journal of Anesthesiology, 2016
Background and objectives: Tourniquet pain is one of the major obstacles for intravenous regional anesthesia. We aimed to compare tramadol and lornoxicam used in intravenous regional anesthesia as regards their effects on the quality of anesthesia ...
Hande Çelik, Ruslan Abdullayev, Erkan Y. Akçaboy, Mustafa Baydar, Nermin Göğüş   +4 more
doaj   +3 more sources

Azeotropic mixture used for development and validation of Lornoxicam in bulk and its tablet dosage form by spectrophotometric method

Journal of Pharmaceutical Analysis, 2012
A novel, safe, economic and sensitive method of spectrophotometric estimation has been developed using Azeoptropic mixture (water:methanol: 60:40, v/v) for the quantitative determination of Lornoxicam, a practically water-insoluble drug.
Prajesh Prajapati, Vipul Vaghela, Deepak Rawtani, Harshad Patel, Jasmin Kubavat, Dharmendra Baraiya   +5 more
doaj   +1 more source

Formulation and characterization of lornoxicam-loaded cellulosic-microsponge gel for possible applications in arthritis

Saudi Pharmaceutical Journal, 2020
Rheumatoid arthritis (RA) is an autoimmune disease associated with severe joint pain. Herein, we report lornoxicam loaded cellulosic microsponge gel formulation with sustained anti-inflammatory effects that are required to manage arthritic pain.
Yeteng He, Khadija Majid, Maimoona Maqbool, Talib Hussain, Abid Mehmood Yousaf, Ikram Ullah Khan, Yasir Mehmood, Ambreen Aleem, Muhammad Sohail Arshad, Adnan Younus, Jorabar Singh Nirwan, Muhammad Usman Ghori, Syed A.A. Rizvi, Yasser Shahzad   +13 more
doaj   +1 more source

Lornoxicam [PDF]

pharma-kritik, 2003
Ein nicht-selektiver Zyklooxygenasehemmer, der zur Behandlung rheumatischer und anderer Schmerzen empfohlen wird. Die Substanz ist nahe mit Tenoxicam verwandt, hat aber eine relativ kurze Halbwertszeit. Nennenswerte Vorteile gegenüber anderen nicht-steroidalen Entzündungshemmern sind nicht auszumachen.
openaire   +1 more source

Characterization of two polymorphs of lornoxicam

Journal of Pharmacy and Pharmacology, 2013
Abstract Objectives The aim of the study was to prepare and to characterize two polymorphs of lornoxicam, a water-insoluble non-steroidal anti-inflammatory drug, which has thus far received no exploration of its polymorphs.
Jianjun, Zhang, Xin, Tan, Jing, Gao, Weiming, Fan, Yuan, Gao, Shuai, Qian   +5 more
openaire   +2 more sources

Assessment of lornoxicam as a mouth dissolving film in management of post extraction pain-A randomized control trial

Journal of Indian Academy of Oral Medicine and Radiology, 2022
Background: Mouth dissolving film (MDF) is a fast-dissolving drug delivery system that provides a practical means to administer drugs not just to special populations with swallowing difficulties but also to the general public. MDFs are novel dosage forms
M Aparna Vijayan, K P Mahesh, Karthikeya Patil   +2 more
doaj   +1 more source

Lornoxicam

, 2006
europepmc   +2 more sources

Preemptive analgesia by lornoxicam--an NSAID--significantly inhibits perioperative platelet aggregation

, 2008
BACKGROUND AND OBJECTIVE: To investigate whether preemptive administered lornoxicam changes perioperative platelet function during thoracic surgery. METHODS: A total of 20 patients scheduled for elective thoracic surgery were randomly assigned to receive
Kimberger, O, Müller, M R, Felfernig, M, Salat, A, Felfernig, D, Gradisek, P   +5 more
core   +1 more source